Home -> Law Blog Directory -> Personal Injury Law Blogs -> Tampa Bay Personal Injury Law
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Personal Injury Law
: Tampa Bay Personal Injury LawActos Users at Risk for Bladder Cancer
By Joe Saunders
The diabetes drug Actos has been associated with bladder cancer and the FDA has now required the manufacturer to provide warnings of this risk. Prior to 2011 Actos manufacturer Takeda Pharmaceutical Company did not warn consumers or physicians of this risk. Takeda never did any medical studies of people before marketing Actos. However, in the rat studies that were done in 1999 there was evidence that Actos caused bladder cancer in the rats. Takeda ignored this evidence from the rat study and marketed the drug to the public anyway.
It appears that Takeda put its own desire for profits ahead of the safety of diabetes patients by selling Actos without proper testing and without a proper warning on the product. This bad conduct on the part of Takeda is the basis for the lawsuits that are now being filed against Takeda on behalf of Actos users who have been diagnosed with bladder cancer.
Bladder cancer is very rare and is treatable if diagnosed early. Early signs of bladder cancer are red tinged urine or blood in the urine. Other causes of bladder cancer are certain dyes used in beauty salons and chemicals sometimes used in leather shops and machine shops.
Actos is a sales name for Pioglitazone. Actos is also sold in combination with metformin under the trade names Actosplus Met and Actosplus Met XR. It is also sold in a combination drug called Duetact.
Actos is in a family diabetes drugs called Thiazolidinediones which are referred to as TZDs. Other diabetes drugs in this class are Rezulin and Avandia. Rezulin was recalled for causing liver damage and Avandia is severely restricted because of its risk of causing heart attacks. I think the FDA may be reluctant to force a recall of Actos because it is the only TZD that can realistically be used anymore. It remains to be seen whether the benefit of Actos can justify the risk of bladder cancer. However, Actos users and their physicians should have been warned of this risk by Takeda.
Diabetes patients should not discontinue Actos or any other drug without consulting their physician. Any diabetes patient who has developed bladder cancer while taking Actos should get legal counsel to advise them of their legal rights because there are is a limited time to bring a lawsuit or it could be barred by the statute of limitations.
Originally posted at InjuryBoard by Joe SaundersFull post as published by Tampa Bay Personal Injury Law on December 18, 2011 (boomark / email).
Actos and Cancer
The FDA is currently investigating a possible association between the diabetes drug Actos (pioglitazone) and an increased risk of bladder cancer. Actos is commonly prescribed to treat type 2 diabetes and works by increasing the body?s sensitivity to insulin...
Does Actos Cause Bladder Cancer
The popular diabetes drug Actos® (pioglitazone), which is marketed as Actos, Actoplus Met, and Duetact, has been linked with an increased risk of bladder cancer. Actos is manufactured and sold by Takeda Pharmaceuticals...
Actos-Related Bladder Cancer: June 2011 Review Of Regulatory Actions And Safety Warnings
FDA And Health Canada Warn About Increased Risk, While France And Germany Suspend Actos Sales (Posted by Tom Lamb at DrugInjuryWatch.com) We will start this Actos - bladder cancer safety review with the most recent announcement, from Health Canada earlier today, June 17, 2011: Health Canada reviewing diabetes drug pioglitazone (Actos) and potential risk of bladder cancer In light of studies suggesting an increased risk of bladder cancer with the diabetes drug pioglitazone, as well as actions taken by other regulatory agencies, Health Canada is informing healthcare professionals and Canadians that it is undertaking a review of the drug's status...
Actos Drug May Increase Risk of Bladder Cancer
Actos (pioglitazaone) has recently been associated with the risk of bladder cancer, according to the FDA. On August 4, 2011, the FDA approved updated drug labels for the pioglitazone-containing medicines to include safety information that continued use of this medication for more than one year can be associated with an increased risk of bladder cancer...
FDA Reviewing Potential Risk of Bladder Cancer with Diabetes Drug Actos
September 17, 2010 The U.S. Food and Drug Administration (FDA) announced today that the agency is reviewing data from an ongoing 10-year study to evaluate whether Actos (pioglitazone) is associated with an increased risk of bladder cancer...
I Took Actos and Have Bladder Cancer Symptoms Whats Next
Recently, the FDA reported that patients using Actos for a year or longer have a substantially increased risk of bladder cancer. Because of this increases risk current and past users of Actos should be aware of the symptoms of bladder cancer and the steps that should be taken if you are experience symptoms...
Pittsburgh Cancer Center
Wanrs of Cell Phone and Cancer Risk
FDA Review of Prostate Cancer Treatment Prompts Warning of Risk for Diabetes
Prostate Cancer Treatment FDA Review Prompts Warning of Risk for Diabetes
Antidepressants
May Increase Risk for Recurrent Cancer
Cell Phone Use
Can Increase Risk of Brain Cancer 5 Times
FenPhen
Serious Heart Problems Found In Ex-Users
Tollway I-Pass
alleging that users were sent erroneous fines










